Anti-KRAS+HRAS+NRAS抗体(ab55391)

发表研究结果有使用 ab55391?请让我们知道,以便我们可以引用本数据表中的参考文章。

ab55391 被引用在 8 文献中.

  • Bäumer S  et al. Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer. Clin Cancer Res 21:1383-94 (2015). WB . PubMed: 25589625
  • Salloum D  et al. Mutant ras elevates dependence on serum lipids and creates a synthetic lethality for rapamycin. Mol Cancer Ther 13:733-41 (2014). PubMed: 24435447
  • Chen M  et al. Use of synthetic isoprenoids to target protein prenylation and Rho GTPases in breast cancer invasion. PLoS One 9:e89892 (2014). Human . PubMed: 24587105
  • Elliott VA  et al. Activation of c-Met and upregulation of CD44 expression are associated with the metastatic phenotype in the colorectal cancer liver metastasis model. PLoS One 9:e97432 (2014). WB ; Mouse . PubMed: 24823486
  • Weisberg E  et al. Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R. Clin Cancer Res 20:5483-95 (2014). PubMed: 25186968
  • Grechukhina O  et al. A polymorphism in a let-7 microRNA binding site of KRAS in women with endometriosis. EMBO Mol Med 4:206-17 (2012). WB ; Human . PubMed: 22307873
  • Scarlett UK  et al. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J Exp Med 209:495-506 (2012). WB ; Human . PubMed: 22351930
  • Espino PS  et al. Genomic instability and histone H3 phosphorylation induction by the Ras-mitogen activated protein kinase pathway in pancreatic cancer cells. Int J Cancer 124:562-7 (2009). WB ; Human . PubMed: 19004007

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"